BMGL Company Profile and Key Details

BMGL has shown mixed momentum, gaining 17.47% over the past week and -50.02% over the past quarter, though year-to-date performance is up 55.04%. Short-term trend indicators are bullishly aligned (SMA20 -6.04%, SMA50 -9.54%, SMA200 -63.33%). The stock’s 14-day RSI is 42.84 (neutral), while the ATR of 0.06 points to moderate volatility. The stock remains hovering near 52-week lows, trading -93.4% below its high and over 27.26% above its low. Average 10-day trading volume of 1.10 thousand shares is below the 3-month average of 20.42 thousand, indicating normal recent market interest.

Basel Medical Group Ltd Ordinary Shares last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $15.82. This means the shares are trading below this model’s fair value.

Basel Medical Group Ltd Ordinary Shares (NASDAQ:BMGL) closed at $4.59 USD, gaining $0.01 (0.22%) from the previous close of $4.58. The stock is currently mid-range between its 52-week high and low $4.17 and $25.80. With a market capitalization of about $7.19 million, Basel Medical Group Ltd Ordinary Shares is classified as a micro-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 21.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Singapore, CE, Basel Medical Group Ltd Ordinary Shares operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Yen Feng Chhoa, the company employs approximately 82 people and listed since February 25, 2025. Basel Medical Group Ltd, an entity established in Singapore in 2023, is dedicated to delivering a comprehensive range of healthcare services.

Basel Medical Group Ltd Ordinary Shares has 1.57 million shares outstanding. The public float is 501.42 thousand shares, elevated short interest at 1.11% of float. This equals 7.91 thousand shares. The short ratio is 0.44 days. Institutional investors hold 0.53% of the float. Insiders own 54.32%.

Our AI price prediction model suggests that Basel Medical Group Ltd Ordinary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.32%, with price expected at $4.30 by September 25, 2026, within a range of $3.83 to $4.75 3-Month Outlook: Projected fall of -2.83%, reaching $4.46 by December 10, 2026, with a range of $2.60 to $6.09. 1-Year Outlook: Projected loss of -42.27%, with price at $2.65 by September 10, 2027, within a range of $1.27 to $3.75.

Basel Medical Group Ltd Ordinary Shares (NASDAQ:BMGL) shares are up 55.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Basel Medical Group Ltd Ordinary Shares trading at a premium to the broader market with a P/E of -16.62. Our AI forecast model points to short-term weakness (-6.32% over two weeks), a medium-term fall (-2.83% over three months), and a longer-term loss (-42.27% over one year), with expected trading ranges indicating moderate volatility.

Basel Medical Group Ltd Ordinary Shares trades at a P/E ratio of -16.62, slightly below the S&P 500 average, with a price-to-sales ratio of 0.64 and a price-to-book ratio of 1.45 suggesting the stock is closer to book value. The P/FCF stands at -3.54, also below market averages.